Substituted Heterocyclic Ethers and Their Use in CNS Disorders
申请人:Degnan Andrew P.
公开号:US20090018132A1
公开(公告)日:2009-01-15
The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.
这项发明涵盖了公式I的化合物,包括药用盐、它们的药物组合物以及它们在治疗中枢神经系统疾病中的用途。
[EN] INDOLES<br/>[FR] INDOLES
申请人:GLAXOSMITHKLINE LLC
公开号:WO2011140324A1
公开(公告)日:2011-11-10
herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
本文揭示了式(I)中吲哚的各种基团的定义,并且这些吲哚对治疗癌症有用。
INDOLES
申请人:GlaxoSmithKline LLC
公开号:US20130345200A1
公开(公告)日:2013-12-26
Herein are disclosed indoles of formula (I)
where the various groups are defined herein, and which are useful for treating cancer.
本文公开了式(I)中各个基团的定义,并且这些化合物对于治疗癌症是有用的。
[EN] SUBSTITUTED HETEROCYCLIC ETHERS AND THEIR USE IN CNS DISORDERS<br/>[FR] ÉTHERS HÉTÉROCYCLIQUES SUBSTITUÉS ET LEUR UTILISATION DANS DES TROUBLES DU SYSTÈME NERVEUX CENTRAL
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2009009411A1
公开(公告)日:2009-01-15
The invention encompasses compounds of Formula (I), including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.
Substituted heterocyclic ethers and their use in CNS disorders
申请人:Bristol-Myers Squibb Company
公开号:US08026257B2
公开(公告)日:2011-09-27
The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.